A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis

Clark, 2003, The prevalence and etiology of elevated aminotransferase levels in the United States, Am J Gastroenterol, 98, 960, 10.1111/j.1572-0241.2003.07486.x Sanyal, 2002, AGA technical review on nonalcoholic fatty liver disease, Gastroenterology, 123, 1705, 10.1053/gast.2002.36572 Harrison, 2003, The natural history of nonalcoholic fatty liver disease, Am J Gastroenterol, 98, 2042, 10.1111/j.1572-0241.2003.07659.x Matteoni, 1999, Nonalcoholic fatty liver disease, Gastroenterology, 116, 1413, 10.1016/S0016-5085(99)70506-8 Marchesini, 1999, Association of nonalcoholic fatty liver disease with insulin resistance, Am J Med, 107, 450, 10.1016/S0002-9343(99)00271-5 Sanyal, 2001, Nonalcoholic steatohepatitis, Gastroenterology, 120, 1183, 10.1053/gast.2001.23256 Reaven, 2004, Obesity, insulin resistance, and cardiovascular disease, Recent Prog Horm Res, 59, 207, 10.1210/rp.59.1.207 McLaughlin, 2003, Use of metabolic markers to identify overweight individuals who are insulin resistant, Ann Intern Med, 139, 802, 10.7326/0003-4819-139-10-200311180-00007 Reaven, 2003, The insulin resistance syndrome, Curr Atheroscler Rep, 5, 364, 10.1007/s11883-003-0007-0 Diraison, 2003, Contribution of hepatic de novo lipogenesis and reesterification of plasma non esterified fatty acids to plasma triglyceride synthesis during non-alcoholic fatty liver disease, Diabetes Metab, 29, 478, 10.1016/S1262-3636(07)70061-7 Turcotte, 2001, Increased fatty acid uptake and altered fatty acid metabolism in insulin-resistant muscle of obese Zucker rats, Diabetes, 50, 1389, 10.2337/diabetes.50.6.1389 Sumida, 2003, Serum thioredoxin levels as a predictor of steatohepatitis in patients with nonalcoholic fatty liver disease, J Hepatol, 38, 32, 10.1016/S0168-8278(02)00331-8 Oliveira, 2002, Oxidative stress in the pathogenesis of nonalcoholic fatty liver disease, in rats fed with a choline-deficient diet, J Cell Mol Med, 6, 399, 10.1111/j.1582-4934.2002.tb00518.x 1998, Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults, Arch Intern Med, 158, 1855, 10.1001/archinte.158.17.1855 Lavine, 2000, Vitamin E treatment of nonalcoholic steatohepatitis in children, J Pediatr, 136, 734, 10.1067/mpd.2000.106566 Fujiwara, 1998, Troglitazone, a new antidiabetic agent possessing radical scavenging ability, improved decreased skin blood flow in diabetic rats, Life Sci, 63, 2039, 10.1016/S0024-3205(98)00482-2 DeFronzo, 1985, Effects of insulin on peripheral and splanchnic glucose metabolism in noninsulin-dependent (type II) diabetes mellitus, J Clin Invest, 76, 149, 10.1172/JCI111938 Brunt, 1999, Nonalcoholic steatohepatitis, Am J Gastroenterol, 94, 2467, 10.1111/j.1572-0241.1999.01377.x DeFronzo, 1979, Glucose clamp technique, Am J Physiol, 237, E214 Frayn, 1983, Calculation of substrate oxidation rates in vivo from gaseous exchange, J Appl Physiol, 55, 628, 10.1152/jappl.1983.55.2.628 Pasquali, 2003, Obesity and reproductive disorders in women, Hum Reprod Update, 9, 359, 10.1093/humupd/dmg024 Lord, 2003, Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome, Cochrane Database Syst Rev, 3, CD003053 Neuschwander-Tetri, 2003, Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone, Hepatology, 38, 1008, 10.1053/jhep.2003.50420 Promrat, 2004, A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis, Hepatology, 39, 188, 10.1002/hep.20012 Ito, 2003, Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates myocardial ischemia/reperfusion injury in a rat model, Lab Invest, 83, 1715, 10.1097/01.LAB.0000106724.29121.DA Berg, 2002, ACRP30/adiponectin, Trends Endocrinol Metab, 13, 84, 10.1016/S1043-2760(01)00524-0 Yamauchi, 2001, The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance, J Biol Chem, 276, 41245, 10.1074/jbc.M103241200 Mofrad, 2003, Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values, Hepatology, 37, 1286, 10.1053/jhep.2003.50229 Clarke, 2001, Nonalcoholic steatosis and steatohepatitis. I. Molecular mechanism for polyunsaturated fatty acid regulation of gene transcription, Am J Physiol, 281, G865 Assimacopoulos-Jeannet, 1995, In vivo effects of hyperinsulinemia on lipogenic enzymes and glucose transporter expression in rat liver and adipose tissues, Metabolism, 44, 228, 10.1016/0026-0495(95)90270-8 Matsuzawa, 1995, Pathophysiology and pathogenesis of visceral fat obesity, Ann N Y Acad Sci, 748, 399, 10.1111/j.1749-6632.1994.tb17336.x Capeau, 2003, Insulin signaling, Med Sci (Paris), 19, 834, 10.1051/medsci/20031989834 Chavez, 2003, Characterizing the effects of saturated fatty acids on insulin signaling and ceramide and diacylglycerol accumulation in 3T3-L1 adipocytes and C2C12 myotubes, Arch Biochem Biophys, 419, 101, 10.1016/j.abb.2003.08.020 Marchesini, 2001, Nonalcoholic fatty liver disease, Diabetes, 50, 1844, 10.2337/diabetes.50.8.1844 Pessayre, 2001, Mitochondria in steatohepatitis, Semin Liver Dis, 21, 57, 10.1055/s-2001-12929 Pessayre, 2002, Nonalcoholic steatosis and steatohepatitis. V. Mitochondrial dysfunction in steatohepatitis, Am J Physiol, 282, G193 Roychoudhury, 2003, Antioxidant vitamins do not prevent cardiovascular disease, J Fam Pract, 52, 751 Clarke, 2002, Antioxidant vitamins and risk of cardiovascular disease. Review of large-scale randomised trials, Cardiovasc Drugs Ther, 16, 411, 10.1023/A:1022134418372